ALFA Finder| Revenue growth | Flat FY27 guidance due to Librela de-stocking headwind. |
|---|---|
| Margins | Mid-20s EBITDA margin targeted through disciplined cost management. |
| Order book | BMS partnership extended to 2035 provides long-term revenue visibility. |
| Demand visibility | Strong pipeline in CDMO biologics and ADC services for FY28. |
| Management confidence | Cautiously optimistic on long-term recovery; defensive regarding near-term flat growth. |
Growth
FY26 revenue grew 3% YoY; Q4 sequential growth of 13% suggests bottoming out despite the Librela impact.
Outlook
Guidance for flat revenue in FY27 with EBITDA margins stabilizing in the mid-20s.
Risks
Heavy client concentration risk with Librela and potential margin pressure from scaling new low-utilization facilities.
Earnings Call filed with NSE, NSE: SYNGENE. Summary written with AI assistance from the document.
Syngene International Ltd: key numbers
- Share price
- ₹446.10
- Market cap
- ₹18,008 Cr
- Revenue (annual)
- ₹3,739 Cr
- Net profit (annual)
- ₹316.7 Cr
- P/E (TTM)
- 96.8×Sector 43.8×
- Promoter holding
- 52.59%+0.00% QoQ
- FII holding
- 10.13%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Syngene International Ltd
All →Syngene International Earnings Call Transcript: Key Takeaways
Syngene reports a transitional quarter with sequential recovery but YoY declines due to the absence of the large Librela revenue stream.
Syngene International Investor Presentation: Key Takeaways
Q2 FY27 revenue Rs 833 Cr (down 9% YoY, up 13% QoQ). Operating EBITDA margin 18% on forex hedge losses. PAT before exceptionals Rs 38 Cr (down 44% YoY). Focus on integrated CRDMO and first Bayview biologics deal.
Syngene International Results Update
Syngene reported Q2 FY27 revenue of Rs 833 Crore, up 13% sequentially, with PAT of Rs 32 Crore. Release includes P&L highlights and business updates.
Syngene International Management Change
Syngene reports changes in senior management: two heads move from SMP to Non-SMP, Ajay Tandon resigns effective October 30, 2026, and CFO Deepak Jain plans to leave. The CFO is a KMP, so this is a material leadership change.
Syngene International Q2 FY27 Results: Net Profit ₹32.2 Cr, Down 52.0% YoY
Syngene International Ltd reported revenue from operations of ₹832.7 Cr (-8.6% YoY) and net profit of ₹32.2 Cr (-52.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹32.2 Cr · -52.0% YoY
Syngene International Other Announcement
Syngene International Limited has submitted the quarterly certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the period ended September 30, 2026.